We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Marfan Syndrome Linked to Skipped Exon

By Biotechdaily staff writers
Posted on 25 Jul 2002
Investigators have found that a mutation in the fibrillin 1 (FBN1) gene causes the nuclear splicing machinery to skip exon 51 entirely, resulting in malfunctioning fibrillin protein activity that affects the integrity of the connective tissue and gives rise to the symptoms associated with Marfan syndrome. More...
This finding was reported in the July 15, 2002, edition of Genes & Development.

Originally characterized in 1896, Marfan syndrome, which may have afflicted US President Abraham Lincoln, is a heritable disorder of the connective tissue, which usually affects the skeletal, respiratory, cardiovascular, and ocular systems, and is commonly associated with tall stature and markedly long limbs.

A mutation in the FBN1 gene was shown more than ten years ago to be linked to the development of Marfan syndrome. The FBN1 gene has 65 exons, or coding regions, that are separated by noncoding introns, which are spliced out of the pre-mRNA transcript during nuclear processing. In the current study researchers from Johns Hopkins University (Baltimore, MD, USA) found that the mutation in exon 51 of the FBN1 gene caused the disruption of an exonic splicing enhancer (ESE), which resulted in exon 51 not being spliced. Proteins produced by the nonspliced exon have compromised function because the region encoded by exon 51 is critical for normal fibrillin protein activity.

This work aids further understanding of the pathogenesis of Marfan syndrome and possibly some of the other human diseases associated with exon skipping.



Related Links:
Johns Hopkins

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Thyroid Test
Anti-Thyroid EIA Test
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.